activity and selectivity considering CYP1A2 is crucial for drug metabolism whereas CYP1A1 is only abundantly expressed in specific malignancies and involved in drug metabolism. In this study, a highly potent and selective CYP1B1 inhibitor C9 was obtained by structural modification, with an inhibitory activity of 2.7 nM against CYP1B1, and more than 37037 and 7407 fold selectivity over CYP1A1 and 1A2
CYP1B1 被认为是治疗癌症的有前途的目标。然而,由于 CYP1B1/1A1/1A2 活性位点之间的密切相似性,考虑到 CYP1A2 对药物代谢至关重要,而 CYP1A1 仅在特定恶性肿瘤中大量表达并参与药物代谢,因此发现兼具活性和选择性的 CYP1B1
抑制剂具有挑战性代谢。本研究通过结构修饰获得了一种高效选择性的CYP1B1
抑制剂C9 ,其对CYP1B1的抑制活性为2.7 nM,对CYP1A1和1A2的选择性分别超过37037和7407倍。此外,C9有效恢复Taxol对A549/Taxol细胞的敏感性,抑制A549/Taxol细胞迁移。分子对接和分子动力学 (MD) 模拟表明,C9在与 CYP1B1 的结合中形成了必要的相互作用,并且可以保持相对稳定。总之,C9可以作为一种有效的选择性 CYP1B1
抑制剂进行进一步研究。